Aldeyra Therapeutics, Inc. (ALDX)

US — Healthcare Sector
Peers: VRCA  VRNA  GRTX  ARQT  PLX  ARDX  ACRS 

Automate Your Wheel Strategy on ALDX

With Tiblio's Option Bot, you can configure your own wheel strategy including ALDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ALDX
  • Rev/Share 0.0041
  • Book/Share 1.062
  • PB 4.0496
  • Debt/Equity 0.2448
  • CurrentRatio 6.39
  • ROIC -0.7724

 

  • MktCap 257587017.0
  • FreeCF/Share -0.7632
  • PFCF -5.6358
  • PE -4.4637
  • Debt/Assets 0.167
  • DivYield 0
  • ROE -0.7257

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation
ALDX
Published: April 14, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / April 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ:ALDX). Investors who purchased Aldeyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALDX.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
ALDX
Published: April 11, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / April 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ:ALDX). Investors who purchased Aldeyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALDX.

Read More
image for news Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect
ALDX
Published: April 10, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ:ALDX). Investors who purchased Aldeyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALDX.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman
ALDX
Published: April 10, 2025 by: PRNewsWire
Sentiment: Neutral

SAN FRANCISCO , April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter ("CRL") from the FDA for the resubmission of the New Drug Application ("NDA") of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. This stark regulatory rejection, which contradicted Aldeyra's repeated assurances of imminent approval, erased over $200 million from the company's market capitalization, prompting investor rights law firm Hagens Berman to launch an investigation into potential securities …

Read More
image for news Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Stockholders to Learn More About the Investigation
ALDX
Published: April 07, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ:ALDX). Investors who purchased Aldeyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALDX.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Stockholders to Learn More About the Investigation
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
ALDX
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out
ALDX
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ:ALDX). Investors who purchased Aldeyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALDX.

Read More
image for news Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out
ALDX NOTIFICATION: Aldeyra Therapeutics, Inc. is being Investigated for Securities Violations after 75% Stock Drop; Investors with Losses are Notified to Contact BFA Law
ALDX
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.

Read More
image for news ALDX NOTIFICATION: Aldeyra Therapeutics, Inc. is being Investigated for Securities Violations after 75% Stock Drop; Investors with Losses are Notified to Contact BFA Law
Did Aldeyra Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– ADLX
ALDX
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ:ADLX) concerning possible violations of federal securities laws. On April 3, 2025, The company disclosed that the FDA issued a second Complete Response Letter (CRL) for reproxalap, Aldeyra's lead dry eye disease drug candidate.

Read More
image for news Did Aldeyra Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– ADLX
ALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA Law
ALDX
Published: April 03, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)---- $ALDX #ALDX--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. Why is Aldeyra Therapeutics being Investigated? Aldeyra Therapeutics is a biotechnology company focused on.

Read More
image for news ALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA Law
ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock Drop Triggers Securities Investigation; Contact BFA Law if You Lost Money (NASDAQ:ALDX)
ALDX
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc.

Read More
image for news ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock Drop Triggers Securities Investigation; Contact BFA Law if You Lost Money (NASDAQ:ALDX)

About Aldeyra Therapeutics, Inc. (ALDX)

  • IPO Date 2014-05-02
  • Website https://www.aldeyra.com
  • Industry Biotechnology
  • CEO Todd C. Brady
  • Employees 9

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.